ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0397

Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire

Margaret Butler1, Carlos Aude2, Clifton Bingham3 and Vivian Bykerk1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Johns Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2023

Keywords: obesity, Patient reported outcomes, quality of care, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the potential impact of elevated BMI on the severity of RA flare symptoms and their effects on quality of life (QOL). Our study addresses this gap, evaluating the influence of BMI on RA flare symptoms and QOL.

Methods: Participants with ≥2 swollen joints and Early/Recent Onset RA (symptoms ≤12/≤24 months) were recruited into the Consortium of Early ArThritis CoHorts-USA Study (CATCH-US) at two centers (New York, Baltimore) between December 2014 and May 2023. Baseline characteristics and patient reported outcomes (PROs) were recorded at each visit. Flares were determined using the OMERACT RA-Flare Questionnaire (RA-FQ), a PRO that assesses symptoms of Pain, Stiffness, Fatigue, and impacts on Physical Function and Social Participation (items scored from 0 to 10; best to worst); all five scores are summed for an overall score range of 0 to 50. An Evaluator Global Assessment (EGA) score, indicating RA clinical disease activity, was scored by the enrolling rheumatologist between 0 (not active) and 10 (very active). Using a multivariable linear regression model, we tested the correlation between BMI and RA-FQ scores, considering EGA scores and demographic factors as covariates.

Results: Eligible participants (n=134) were mostly female (85%), white (71%), and non-Hispanic (87%); almost half were overweight or obese (46%); median age was 47.3 years and median BMI was 24.3 (Table 1). Higher EGA scores (β = 2.3; p < .001) and elevated BMI (β = 0.38; p = .01) emerged as significant predictors of higher RA-FQ scores; EGA was also significantly associated with each RA-FQ subscore, while BMI was significantly associated with four of the five subscores (Table 2). We observed an amplified impact of elevated BMI on RA-FQ scores in obese patients compared to those in healthy weight and overweight categories (Figure 1). Age was inversely related to the total RA-FQ score (β = -0.11; p = .04) and Function subscore (β = -0.03; p = .01). No significant associations were found for sex, race, or ethnicity.

Conclusion: Our findings underscore a strong correlation between EGA scores and RA-FQ scores, thereby establishing the concordance of this PRO with clinically assessed disease activity. More importantly, we found that elevated BMI is associated with more severe flare activity and diminished QOL, particularly in obese ERA patients. This result corroborates earlier studies that suggested a systematic underestimation of disease activity in patients with elevated BMI. As such, clinicians should consider patients’ BMI and RA-FQ scores when formulating treatment plans for RA flares. Future research will focus on longitudinal analyses to assess the persistence of these associations throughout the course of the disease.

References:
1. Schulman, E., et al, Arthritis Care Res (Hoboken), 2018.70(8)
2. Bauer, E.M., et al. BMC Musculoskelet Disord, 2017.18(1)

Supporting image 1

Table 1. Patient Characteristics

Supporting image 2

Table 2. Multivariable Linear Regression Results for RA-FQ Score and Individual RA-FQ Subscores, displaying Adjusted Betas with 95% Confidence Intervals for all analyzed variables.

Supporting image 3

Figure 1. Forest Plot of Adjusted Betas with 95% Confidence Intervals illustrating the impact of Evaluator Global Assessment (EGA) and BMI on RA-FQ scores. BMI is presented as both a categorical and continuous variable; the continuous BMI variable is scaled such that the RA-FQ score is predicted to shift approximately 2.3 points for each standard deviation that the BMI increases/decreases (SD = 5.9).


Disclosures: M. Butler: None; C. Aude: None; C. Bingham: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 2, Janssen, 2, Pfizer, 2, Sanofi, 2; V. Bykerk: Abbvie, 2, BMS, 2, Pfizer, 2.

To cite this abstract in AMA style:

Butler M, Aude C, Bingham C, Bykerk V. Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/obesity-is-associated-with-worse-flare-symptoms-and-quality-of-life-in-early-rheumatoid-arthritis-insights-from-the-ra-flare-questionnaire/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-is-associated-with-worse-flare-symptoms-and-quality-of-life-in-early-rheumatoid-arthritis-insights-from-the-ra-flare-questionnaire/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology